Oral treatment for light sensitivity in EPP and XLP
Part of Digestive system, Genetic & congenital, Hormones & metabolism, Skin clinical trials.
This study tests an oral medication, PORT-77, to reduce pain and sensitivity to sunlight in people with EPP or XLP. It may help those who experience symptoms shortly after sun exposure.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be at least 12 years old
- Have a confirmed diagnosis of EPP or XLP
- Experience symptoms of sun sensitivity within about 45 minutes of sun exposure
- Be willing to fill out a daily symptom diary and follow study procedures
- Meet weight or body mass index (BMI) criteria (weight ≥32 kg for ages 12-17, BMI ≥18.5 for adults)
- Not be taking certain light-sensitivity medications or supplements (e.g., afamelanotide, beta carotene) within 90 days before the study starts
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tracks how your body reacts to sunlight if you have erythropoietic protoporphyria (EPP) or X-linked protoporphyria (XLP)—rare genetic conditions that cause painful skin reactions to sun exposure. Researchers will use special devices and daily logs to better understand your symptoms and how light affects your skin.
This program provides access to an experimental drug called bitopertin, which may help reduce the severe light sensitivity and pain caused by EPP or XLP. It's for people aged 12 and older who have not had success with other treatments.
This Phase 2 study tests whether using a lower light dose during a treatment called Hemoporfin PDT can safely shrink port-wine birthmarks (PWB). It aims to find a dose that works well while causing fewer side effects.
This trial tests an oral drug called enpatoran for people with lupus that causes skin rashes (like discoid or subacute cutaneous lupus). The goal is to see if the drug can improve these skin symptoms.
This trial tests an oral medication called ciclopirox (ATL-001) to see if it can reduce skin sensitivity to sunlight in adults with CEP. It aims to improve the skin lesions caused by this rare disease.
This trial studies how safe and well bitopertin works over the long term for people with EPP. It mainly includes people who already finished an earlier bitopertin study, to keep tracking side effects and overall progress.
Hear when a new Erythropoietic Protoporphyria (EPP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.